231296-98-3

Basic information

• Product Name: (E)-methyl 3-(2-amino-5-(trifluoromethyl)phenyl) acrylate
• Synonyms: (E)-methyl 3-(2-amino-5-(trifluoromethyl)phenyl) acrylate
• CAS NO: 231296-98-3
• Molecular Weight: 245.201
• Mol File: 231296-98-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (E)-methyl 3-(2-amino-5-(trifluoromethyl)phenyl) acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-methyl 3-(2-amino-5-(trifluoromethyl)phenyl) acrylate(231296-98-3)
• EPA Substance Registry System: (E)-methyl 3-(2-amino-5-(trifluoromethyl)phenyl) acrylate(231296-98-3)

Safety Data

• Hazardous Substances Data: 231296-98-3(Hazardous Substances Data)

Upstream product

• 292638-85-8 acrylic acid methyl ester 
• 57946-63-1 4-amino-3-bromobenzotrifluoride 
• 6163-58-2 tris-(o-tolyl)phosphine 

Downstream Products

• 835903-14-5 6-(trifluoromethyl)-1,2-dihydroquinolin-2-one 
• 1421348-42-6 C₂₅H₂₆F₃N₃O₃ 
• 78060-56-7 2-chloro-6-(trifluoromethyl)quinoline 

Relevant articles and documents

ISOINDOLINES AS HDAC INHIBITORS

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.

QUINOLINYL GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

2,3-substituted indole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4.This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.